KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Share-based Compensation (2016 - 2025)

Inovio Pharmaceuticals' Share-based Compensation history spans 16 years, with the latest figure at $757086.0 for Q3 2025.

  • For Q3 2025, Share-based Compensation fell 38.94% year-over-year to $757086.0; the TTM value through Sep 2025 reached $4.3 million, down 42.92%, while the annual FY2024 figure was $6.6 million, 40.44% down from the prior year.
  • Share-based Compensation for Q3 2025 was $757086.0 at Inovio Pharmaceuticals, down from $834792.0 in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.6 million in Q1 2021 and bottomed at $757086.0 in Q3 2025.
  • The 5-year median for Share-based Compensation is $2.9 million (2023), against an average of $3.7 million.
  • The largest annual shift saw Share-based Compensation skyrocketed 139.81% in 2021 before it crashed 65.0% in 2023.
  • A 5-year view of Share-based Compensation shows it stood at $5.5 million in 2021, then tumbled by 40.18% to $3.3 million in 2022, then tumbled by 30.79% to $2.3 million in 2023, then crashed by 41.94% to $1.3 million in 2024, then plummeted by 42.46% to $757086.0 in 2025.
  • Per Business Quant, the three most recent readings for INO's Share-based Compensation are $757086.0 (Q3 2025), $834792.0 (Q2 2025), and $1.4 million (Q1 2025).